Your session is about to expire
← Back to Search
Brentuximab + Crizotinib Chemotherapy for Lymphoma
Study Summary
This trial is studying brentuximab vedotin and crizotinib in combination with chemotherapy to see if they are more effective than crizotinib and chemotherapy alone in treating patients with newly diagnosed stage II-IV anaplastic large cell lymphoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 4 trial • 60 Patients • NCT01990534Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I weigh more than 10 kg.My liver is functioning well, with normal bilirubin levels.My heart is strong, with a good pumping efficiency.I haven't had steroids or radiation unless it was for an urgent issue with my chest mass.My cancer has spread beyond just my skin.My cancer is not at stage I.I've had spinal chemotherapy for ALCL, but tests show no ALCL in my spinal fluid now.I do not have Down syndrome.My cancer is ALK positive.My lab results are off due to my lymphoma, but I can adjust my treatment dose.I can breathe normally without feeling short of breath and my oxygen level is above 92%.I haven't taken strong CYP3A4 inducer drugs in the last 12 days.I haven't taken strong CYP3A4 inhibitor drugs or grapefruit juice in the last week.I am not pregnant and if capable, have had a pregnancy test.I do not have a pre-existing immunodeficiency or have received an organ transplant.I am not taking medications like pimozide or triazolam regularly.My cancer is at stage II, III, or IV.I have not had chemotherapy for my current ALCL or any past cancer.My liver enzyme (ALT) levels are within the normal range for my age.My disease is CD30 positive.I have been newly diagnosed with ALCL.I do not have a brain or spinal cord disease.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: Arm BV (brentuximab vedotin, combination chemotherapy)
- Group 2: Arm CZ (crizotinib, combination chemotherapy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
Could you walk me through the other research studies that have included Brentuximab Vedotin?
"Currently, there are a total of 1969 clinical trials studying the efficacy of Brentuximab Vedotin. Out of those, 420 are in Phase 3. The majority of these studies originate from Mishawaka, Indiana; however, there are 67819 research sites running investigations on this medication."
Are other healthcare facilities also conducting this experiment within the state's borders?
"Currently, this trial has 100 patients that have signed up, which comes from locations such as Laura and Isaac Perlmutter Cancer Center at NYU Langone in New york, Roswell Park Cancer Institute in Buffalo, Golisano Children's Hospital of Southwest Florida in Fort Myers."
Are patients currently being recruited for this research project?
"Data from clinicaltrials.gov indicates that this trial is not currently looking for patients to enroll. Although, it is worth noting that there are 3765 other trials similar to this one which ARE recruiting patients. This particular study was posted on November 8th, 2013 and last updated September 24th, 2022."
Has Brentuximab Vedotin passed clinical trials in the United States?
"While Phase 2 trials don't usually have data supporting efficacy, Brentuximab Vedotin's safety has been supported by some clinical data and received a score of 2."
How many test subjects are needed for this experiment?
"This study is not enrolling new patients at this time, as the last update was on September 24th, 2022. However, there are other ongoing clinical trials that may be of interest. There are currently 1796 active studies recruiting participants with lymphoma and 1969 for Brentuximab Vedotin."
Has a similar trial been conducted before?
"Brentuximab Vedotin has undergone 3337 clinical trials since 1997. These studies are still ongoing in 87 different countries and across 3320 cities. The earliest trial, sponsored by Alfacell, reached Phase 3 approval with 300 patients enrolled."
Share this study with friends
Copy Link
Messenger